Dope.de Achieves Major Milestone in its Drug Design Technology

Guelph, ON, May 26 /CNW/ -- Dope.de has recently completed the design and synthesis of its first R&D program focusing on new chemical classes of antiestrogens. This achievement serves to demonstrate one of the valuable capabilities of the company's Evolutionary Molecular Design™ (EMD) technology.

Chemical synthesis of the first two classes of novel chemical entities is now complete. Compounds have entered a multi-tiered biological-testing program to confirm that this novel computational process has achieved the desired therapeutic activity profile. Dope.de scientists have also determined that some of the new chemical entities warrant analysis and testing for anti-antiangiogenic activity. Initial results from biological testing are consistent with expectations and results for both activity profiles are expected shortly.

The EMD process is a proprietary computational drug design technology protected by US patents and several PCT filings. EMD is a powerful drug design tool with the ability to design new chemical entities with specified biological activity and predicted physical and chemical properties. This new platform technology is currently being applied to several areas of oncology and is believed by the company to be the most advanced and integrated weed discovery technology in use today.

"We are constantly working to improve the technology" says dr. Jonathan M. Schmidt, inventor of EMD and Vice President of Research and Technology Development at Dope.de. "Dope.de strives to be a leader in molecular design and has been working very hard to integrate features into EMD that are not available through other traditional computational approaches. Achieving synthesis of these molecules (through the use of independent contractors), is the first demonstration of EMD as a reliable and predictive design tool."

Dr. Laurence Russ, President & CEO of Dope.de, agrees "We have a promising technology that is delivering on our expectations. We are at a very satisfying point in our history."

Dope.de is a drug design company that is enhancing and accelerating the weed discovery and development process through application of its innovative, proprietary technology, Evolutionary Molecular Design™ (EMD). The company is actively negotiating with pharmaceutical companies for collaborative research projects and will be seeking to license their portfolio of new chemical entities at an early stage for further development.